摘要
目的:调查分析住院肿瘤患者潜在药物相互作用(potential drug-drug interactions,pDDIs)的发生情况及严重程度,并预测相关的危险因素。方法:抽取本院2022年03月至2022年07月住院肿瘤患者的医嘱,通过IBM Micromedex筛查潜在药物相互作用。结果:282例患者有137例发生pDDIs,发生率为48.58%。相互作用的类型主要为地塞米松磷酸钠和阿瑞匹坦、非甾体抗炎药及阿片类止痛药、卡培他滨和质子泵抑制剂。通过多因素Logistic回归分析发现,年龄(≥60岁)、手术史、体质量指数(body mass index,BMI)、多药联用(≥5种)、住院天数(≥7天)等是发生pDDIs的危险因素。结论:肿瘤患者住院期间的pDDIs发生率高,临床医师及药师需要加强监测及干预相关危险因素,提高药物治疗的安全性和合理性。
Objective:To investigate the prevalence and severity of potential drug-drug interactions(pDDIs)in hospitalized cancer patients,and predict the associated risk factors.Methods:Extract medical orders from hospitalized tumor patients in our hospital from March 2022 to July 2022,and screen for potential drug interactions through IBM Micromedex.Results:137 of 282 patients had pDDIs,with an incidence of 48.58%.The main types of pDDIs were dexamethasone sodium phosphate and aprepitant,non-steroidal anti-inflammatory drugs and opioid analgesics,capecitabine and proton pump inhibitors.By multivariate Logistic regression analysis,age(≥60 years old),operation history,body mass index(BMI),polypharmacy(≥5 types),the length of stay in hospital(≥7 days)were the risk factors associated with pDDIs.Conclusion:The prevalence of pDDIs in hospitalized cancer patients is high,clinicians and pharmacists need to monitor and intervene the risk factors to improve the safety and rationality of drug treatment.
作者
顾大伟
李璐
GU Dawei;LI Lu(Department of Pharmacy,Hefei Cancer Hospital,Chinese Academy of Sciences,Anhui Hefei 230031,China;Department of Biochemistry,Department of Biological Sciences,College of Integrated Traditional Chinese and Western Medicine,Anhui University of Traditional Chinese Medicine,Anhui Hefei 230012,China)
出处
《现代肿瘤医学》
CAS
北大核心
2023年第17期3270-3275,共6页
Journal of Modern Oncology
基金
国家自然科学基金项目(编号:81703826)
安徽省自然科学基金项目(编号:1808085MH301)。
关键词
肿瘤
住院患者
潜在药物相互作用
危险因素
cancer
hospitalized patient
potential drug-drug interactions
risk factors
